Advertisement

Advertisement

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Hematologic Malignancies
Immunotherapy

Bispecific Antibodies: Successes and Challenges

Bispecific T-cell engager (BiTE) antibodies, such blinatumomab, may be the most appealing type of bispecific antibodies, a class of manufactured constructs that is expected to expand into the solid tu...

Pancreatic Cancer

Study Focuses on Role of Microbes in Pancreatic Cancer

Although bacteria are predominant in the gastrointestinal tract, they also reside on and in other parts of the body, including some unexpected places, such as malignant tumors. There are numerous repo...

Kidney Cancer
Immunotherapy

Expert Point of View: Navid Hafez, MD, MPH

Ilixadencel is essentially a dendritic cell vaccine without preloaded antigens. In the MERECA study, ilixadencel produced “a great signal,” though this approach is still very experimental, said the st...

Kidney Cancer
Immunotherapy

Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer

Ilixadencel is a cell-based, allogeneic, off-the-shelf product aimed at priming the anticancer immune response when injected intratumorally. The phase II MERECA study evaluated this allogeneic dendrit...

Immunotherapy
Symptom Management

Expert Point of View: Jarushka Naidoo, MBBCh

“The investigators of the current study tested the hypothesis that vitamin D supplementation is associated with a reduced risk of checkpoint-induced colitis by rigorously assessing 37 variables in bot...

Immunotherapy
Symptom Management

Vitamin D Supplementation May Protect Against Checkpoint Inhibitor–Induced Colitis

Vitamin D supplementation prior to starting immune checkpoint inhibitor therapy may significantly reduce the odds of developing colitis, according to a study conducted at Harvard Medical School. Altho...

Immunotherapy

Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients

As the number of solid organ transplants in the United States rises, cancer in this patient population is a growing concern. In fact, solid organ transplant recipients have an up to 50 times greater r...

lung cancer

Jarrett Failing, MD, on Human Leukocyte Antigen Expression in NSCLC With Brain Metastases

Jarrett Failing, MD, of the Mayo Clinic, discusses his study data, which show some agreement between the expression of human leukocyte antigens in primary non–small cell lung cancer with brain metasta...

skin cancer
immunotherapy

John N. Lukens, MD, on Advanced Melanoma: Antibiotics, Survival, and Colitis in Patients Receiving Immunotherapy

John N. Lukens, MD, of the Hospital of the University of Pennsylvania, discusses his finding that taking antibiotics within 3 months of starting treatment with immune checkpoint inhibitors may lead to...

gynecologic cancers
immunotherapy

Christopher B. Cole, MD, PhD, on Ovarian Cancer: First-in-Human Study of Interferon-Activated Autologous Monocytes

Christopher B. Cole, MD, PhD, of the National Cancer Institute, discusses findings from a phase I study of intraperitoneal monocytes activated by interferons alpha and gamma in patients with ovarian c...

immunotherapy
symptom management
skin cancer

Kevin Tyan on Colitis Induced by Immune Checkpoint Inhibitors: Potential Preventive Strategy

Kevin Tyan, of Kinnos, and currently a medical school student at Harvard University, discusses his study findings, which showed that patients with melanoma who are treated with immunotherapy had a sig...

immunotherapy

Jacob J. Adashek, DO, on Immunoregulatory Molecules, Cancer Genes, and Therapeutic Insights

Jacob J. Adashek, DO, of the University of South Florida and Moffitt Cancer Center, discusses data on combining immunoregulatory inhibition and targeted gene therapy, which may offer patients better o...

Martin McCarter, MD, on Refinement of Surgical Treatment: Expert Perspective on ASCO’s 2020 Advance of the Year

Martin McCarter, MD, of the University of Colorado Denver, discusses the recent strides in surgical oncology, how the role of surgery has changed, and what lies ahead for this staple of cancer therapy...

skin cancer
immunotherapy

Philippa G. Corrie, PhD, on Patient Outcomes in Melanoma After Immune Checkpoint Inhibition

Philippa G. Corrie, PhD, of Cambridge University Hospitals NHS Foundation Trust, discusses a review of 2,322 patients with metastatic melanoma receiving first-line immune checkpoint inhibitors as stan...

pancreatic cancer
immunotherapy

Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D

Luis I. Ruffolo, MD, of the University of Rochester, discusses preclinical studies showing that semaphorin 4D blockade may sensitize pancreatic tumors to chemoimmunotherapy combinations (Abstract 26).

immunotherapy

Dario Vignali, PhD, on Immune Resistance Mechanisms in Cancer

Dario Vignali, PhD, of the University of Pittsburgh and UPMC Hillman Cancer Center, summarizes his Keynote Address, which covered what drives systemic immune dysfunction in patients with cancer, what ...

skin cancer
breast cancer
lung cancer

Elizabeth A. Mittendorf, MD, PhD, on Mobilizing the Immune System to Treat Select Solid Tumors

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, summarizes a session she co-chaired on utilizing the immune system in neoadjuvant trials to treat me...

Kidney Cancer
Immunotherapy

ASCO-SITC 2020: Ilixadencel/Sunitinib vs Sunitinib Alone in Synchronous Metastatic Kidney Cancer

In a study presented by Lindskog et al at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium (Abstract 11), researchers found ilixadencel, a cell-based allogeneic off-the-shelf product, in combinat...

Lung Cancer
Immunotherapy
Symptom Management

ASCO-SITC 2020: Low Incidence of Nivolumab-Induced Radiation Recall Pneumonitis Among Patients With NSCLC

A multicenter retrospective study investigating the incidence of pneumonitis and the incidence, risk factors, and clinical characteristics of radiation recall pneumonitis in patients with non–small ce...

Lung Cancer
Immunotherapy

ASCO-SITC 2020: Preliminary Results Show Antitumor Activity With Pepinemab/Avelumab in Patients With Advanced NSCLC

Interim results from the CLASSICAL-Lung phase Ib/II clinical trial of pepinemab, an IgG4 humanized monoclonal antibody targeting semaphorin 4D, in combination with the anti–programmed cell death ligan...

Immunotherapy
Symptom Management

ASCO-SITC 2020: Vitamin D May Reduce Risk for Immune Checkpoint Inhibitor–Associated Colitis

In a study to be presented by Tyan et al at the upcoming 2020 ASCO-SITC Clinical Immuno-Oncology Symposium (Abstract 89), researchers found that vitamin D intake may be associated with reduced risk of...

Advertisement

Advertisement



Advertisement